The authors showed that TCL@PDA NPs delayed cancer progression in tumor-bearing mice, promoted antigen uptake, bone-marrow-derived dendritic cell (BMDC) maturation, and Th1-related cytokine secretion, while conferring long-term protection against tumors via CD4+ and CD8+ T cell enhancement. This evidence concerns the gene CD8A and neoplasm.